Chronic use of NSAIDs and/or statins does not affect PSA or PSA velocity in men at high risk for prostate cancer

PSA and PSA velocity (PSAV, rate of PSA change over time) are biomarkers for diagnosis and prognosis of prostate cancer. Men who are at high risk for prostate cancer also have associated comorbidities for which they are taking NSAIDs and statins for long periods; therefore, it is important to understand the effect of these medications on markers used to assess prostate cancer risk. Using a population of 699 men, multiple linear regressions were used to investigate the associations between PSA and concomitant medications, and mixed-effects models were used to investigate these associations with PSAV. After adjusting for selenium use, age, race, body mass index, and pack-years of smoking, aspirin, other NSAIDs, or statins did not demonstrate statistically significant associations with PSA (P = 0.79, 0.68, and 0.79, respectively) or PSAV (P = 0.23, 0.43, and 0.84, respectively). Results were not altered upon stratifying the sample between men who developed prostate cancer during the course of the study and those who did not. Results from this study indicate that chronic use of aspirin, other NSAIDs, or statins did not affect PSA levels or PSAV in men at high risk for prostate cancer. Larger prospective studies designed to investigate these relationships are needed to confirm this result. Long-term use of NSAIDs or statins in men at high risk for prostate cancer may not interfere with the diagnosis or prognosis of this disease, and supports appropriate use of these medications with regard to prostate cancer risk.